A Study of Evacetrapib and Rifampin in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/5/2018 |
| Start Date: | July 2013 |
| End Date: | September 2013 |
Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects
The main purpose of this study is to determine how much evacetrapib gets into the blood
stream and how long it takes the body to get rid of it when given with rifampin. The safety
and tolerability of the two drugs, given together, will also be evaluated. The study will
also look at blood cholesterol levels and levels of a hormone called cortisol before and
after taking rifampin. Information about any side effects that may occur will also be
collected.
For each participant, this study will include 2 periods in fixed order. The study will last
approximately 29 days.
stream and how long it takes the body to get rid of it when given with rifampin. The safety
and tolerability of the two drugs, given together, will also be evaluated. The study will
also look at blood cholesterol levels and levels of a hormone called cortisol before and
after taking rifampin. Information about any side effects that may occur will also be
collected.
For each participant, this study will include 2 periods in fixed order. The study will last
approximately 29 days.
Inclusion Criteria:
- Overtly healthy males and females (of non child-bearing potential)
- Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2), inclusive, at
screening
Exclusion Criteria:
- Have known allergies to evacetrapib, rifampin, related compounds or any components of
either formulation, or history of significant allergic disease as determined by the
investigator
We found this trial at
1
site
Click here to add this to my saved trials
